We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Blood Test Tracks and Follows Neurodegeneration in Alzheimer's

By LabMedica International staff writers
Posted on 19 Jan 2023

Researchers have been recently making significant efforts to identify biomarkers in blood that could help to diagnose and monitor Alzheimer’s disease (AD). More...

The key focus of their extensive research in the biomarker field has been on tau – one of the main proteins involved in AD pathology. In the last few years, the appearance of new blood-based phosphorylated tau markers for AD have demonstrated that it is possible to develop an accessible and effective test for screening patients with suspected AD. However, a key challenge has been measuring brain proteins in blood despite the currently available technologies. Now, scientists have leveraged architectural differences in the structure of tau protein found in the brain versus peripheral sources to engineer a novel antibody that specifically targets tau isoforms originating from the brain.

This breakthrough by researchers at University of Gothenburg (Gothenburg, Sweden) has led to the development of a new blood test that specifically and selectively measures non-phosphorylated tau coming from the brain into the bloodstream. The innovation meets an urgent unmet need for a blood test that can track neurodegenerative changes specifically in AD but not in other dementias. The new brain derived tau (BD-tau) assay has demonstrated robust and stable technical performances in blood. Clinically, the researchers found a strong correlation between BD-tau levels in blood and CSF, suggesting that the assay was measuring brain tau.

A collaborative study by researchers from Italy, the U.S. and Sweden measured BD-tau levels in blood samples from 609 patients. In a cohort of individuals with autopsy-verified diagnosis, plasma BD-tau was seen to be a marker of neurodegeneration that differentiated AD from non-Alzheimer dementias. Interestingly, instead of neurofilament light (NfL), plasma BD-tau correlated with amyloid plaque and tau tangle loads in the brains of these individuals, further demonstrating its specificity to AD. In order to demonstrate the clinical utility of these results, the researchers analyzed two separate memory clinic cohorts where the participants had been diagnosed with AD, other dementias or controls. The researchers found that plasma BD-tau once again showed high accuracy in differentiating AD from other dementias and also outperformed plasma NfL. Based on these results, plasma BD-tau can be considered as a new blood-based biomarker that is capable of distinguishing between AD and other type of dementias. Moreover, unlike other blood-based biomarkers such as NfL, BD-tau is capable of uniquely reflecting the extent of neurodegeneration in patients with AD.

The proposed framework developed by the National Institutes on Aging and the Alzheimer’s Association to identify and stage the progress of AD using biological evidence, focuses on biomarkers of amyloid (A), tau (T), and neurodegeneration (N). The framework, referred to as the AT(N) model, has been authenticated using cerebrospinal fluid (CSF) and neuroimaging biomarkers. The CSF AT(N) markers include amyloid-beta (Aβ42/40), phosphorylated-tau (p-tau), and total tau. However, full implementation of the AT(N) system using blood biomarkers has not been possible due to the absence of an N marker that shows specificity to Alzheimer pathophysiology. Plasma BD-tau allows to complete the AT(N) scheme in blood as a true neurodegeneration marker that is specific to Alzheimer-type pathology. From the research perspective, BD-tau will prove useful in understanding the neurodegenerative processes in AD and how they are different from those in other dementias. From the clinical perspective, BD-tau can be easily implemented as a quick and accessible blood test for diagnosing and monitoring disease progression in patients with AD.


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Staining System
RAL DIFF-QUIK
New
Automated Biochemical Analyzer
iBC 900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.